Cargando…

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study

BACKGROUND: Regorafenib has been demonstrated as effective in refractory metastatic colorectal cancer. Combination use with chemotherapy has not been reported. We examined the efficacy and safety of adding chemotherapy to Regorafenib for the treatment of metastatic colorectal cancer(mCRC) patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chun-Yu, Lin, Tseng-Hsi, Chen, Chou-Chen, Chen, Ming-Cheng, Chen, Chou-Pin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755875/ https://www.ncbi.nlm.nih.gov/pubmed/29304109 http://dx.doi.org/10.1371/journal.pone.0190497

Ejemplares similares

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
por: Xu, Donghao, et al.
Publicado: (2022)

Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study
por: Liao, Po-Wei, et al.
Publicado: (2022)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study
por: Su, Mao, et al.
Publicado: (2022)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
por: Aljubran, Ali, et al.
Publicado: (2019)

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study
por: Zhou, Hong, et al.
Publicado: (2021)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
por: Tanaka, Akira, et al.
Publicado: (2018)

Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
por: Ogata, Misato, et al.
Publicado: (2020)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
por: Belli, Valentina, et al.
Publicado: (2017)

Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study
por: Cao, Guang, et al.
Publicado: (2022)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment
por: Su, Yu-Li, et al.
Publicado: (2021)

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
por: Aydin, Sabin Goktas, et al.
Publicado: (2023)

Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread
por: Hsu, Hung-Chih, et al.
Publicado: (2021)

Tattooing or Metallic Clip Placement? A Review of the Outcome Surrounding Preoperative Localization Methods in Minimally Invasive Anterior Resection Performed at a Single Center
por: Lin, Chang-Lin, et al.
Publicado: (2021)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Is neutrophil-to-lymphocyte ratio and C-reactive protein the prognostic role in metastatic colorectal cancer using regorafenib?
por: Chen, Xinyang, et al.
Publicado: (2023)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer
por: Ebinç, Senar, et al.
Publicado: (2022)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
por: Li, Jisheng, et al.
Publicado: (2020)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
por: Xu, Jianming, et al.
Publicado: (2020)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
por: Khan, Gazala, et al.
Publicado: (2014)

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
por: Arai, Hiroyuki, et al.
Publicado: (2017)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
por: Yoshino, Kenji, et al.
Publicado: (2017)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ba6uu3s8902ka9e7der9qtgjkp